双眼急性梅毒性后部鳞状脉络膜视网膜炎1例

2017-12-19 佚名 中华眼底病杂志

患者男,54岁

【一般资料】

患者男,54岁

【主诉】

因右眼视力下降2周、左眼视力下降2个月于2016年1月21日来我院就诊。

【现病史】

患者4个月前无明显诱因出现发热伴双下肢皮肤红斑,外院诊断为紫癜;给予口服泼尼松10mg,3次/d,体温恢复正常,但双下肢皮肤红斑无改变。治疗10余日后患者自行停服泼尼松,症状反复,泼尼松调整为60mg,同时联合来氟米特10mg口服,治疗10余日后双下肢皮肤红斑逐渐消失。2周后患者再次自行将泼尼松减至20mg,体温升至39.8℃并伴腹痛,同时左眼出现视力下降。外院检查,抗核抗体1:320,C反应蛋白(CRP)升高,诊断为系统性红斑狼疮。继续给予泼尼松30mg及奥美拉唑口服。治疗后体温降至正常,腹痛缓解;左眼症状则继续加重。外院眼科检查:右眼矫正视力0.6,左眼矫正视力0.03。左眼眼前节检查未见异常;眼底视盘边界欠清楚。右眼眼前节及眼底检查未见异常。诊断为左眼缺血性视神经视网膜病变。给予营养神经及改善循环药物治疗,视力无改善。1个半月前左眼矫正视力降至0.01,瞳孔散大固定,视盘边界欠清楚,黄斑区色素紊乱,中心凹反光消失。外院诊断为左眼后极部视网膜色素上皮(RPE)改变(原因待查),未给予治疗。1个月前患者来我院免疫内科就诊。实验室检查,血、尿常规以及红细胞沉降率、抗中性粒细胞胞浆抗体、补体、类风湿因子、抗人球蛋白试验、狼疮抗凝物及β2糖蛋白1均正常,抗心磷脂抗体阳性,高敏CRP升高。诊断为结缔组织病,系统性红斑狼疮可除外。给予口服泼尼松30mg,1次/d,联合环磷酰胺100mg,隔日1次。治疗后左眼视力无明显好转。2周前患者右眼视力突然下降就诊于我院眼科。

【体格检查】

右眼矫正视力0.06,左眼矫正视力0.1。双眼角膜后细小灰白尘状及少量色素洼沉着,前房深,房水闪辉(+),浮游体(+);瞳孔对光反射迟缓,右眼直径2.5mm,左眼直径4.0mm。双眼视盘边界欠清楚,后极部视网膜呈灰黄色,局部色素紊乱,黄斑中心凹反光消失;右眼视盘周围数个棉絮斑(图1A,1B)。荧光素眼底血管造影(FFA)检查,双眼后极部湖形强荧光区,其内多个弱荧光点,呈“豹斑状”(图1C,1D)。

【辅助检查】

眼底自身荧光(FAF)检查,可见与FFA对应的后极部强荧光区,其内多个弱荧光点(图1E,1F)。光相干断层扫描(OCT)检查,双眼外界膜消失,椭圆体带节段性缺失;RPE层不规则增厚,局部多个细小结节状隆起;脉络膜层散在点状强信号(图lG,1H)。视野检查,双眼中心及旁中心暗点。依据病史、临床表现及相关检查结果,高度怀疑眼部梅毒感染,行与感染相关检查。梅毒螺旋体明胶凝集试验、梅毒螺旋体特异性抗体及快速血浆反应素均为阳性,人类免疫缺陷病毒(HIV)Ag/Ab阳性。

【既往史】

再次追问病史,患者存在冶游史。

【初步诊断】

双眼急性梅毒性后部鳞状脉络膜视网膜炎(ASPPC);梅毒合并HIV感染。

【治疗】

参照文献的方法给予驱梅治疗。苄星青霉素2.40MU肌肉注射治疗,1次/周。驱梅治疗3个月后患者自觉全身及眼部症状好转。检查,双眼矫正视力0.6;眼前节及眼底未见异常。OCT检查,双眼椭圆体带连续,RPE层厚度恢复正常,其局部结节状隆起消失,脉络膜点状强信号明显减少。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1751393, encodeId=5d561e51393d5, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03036305261, createdName=Tommy1961, createdTime=Tue Dec 19 19:50:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687007, encodeId=90af168e00780, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Jul 19 13:50:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272766, encodeId=a56d2e2766d8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/19/65b621d4a385e517982f632daf4124bb.jpg, createdBy=93302217036, createdName=李香香, createdTime=Tue Dec 26 21:52:18 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269988, encodeId=59ec126998860, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Dec 21 03:50:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270907, encodeId=6a972e090781, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Dec 20 12:26:49 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270650, encodeId=755f2e065008, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Dec 19 15:15:51 CST 2017, time=2017-12-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1751393, encodeId=5d561e51393d5, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03036305261, createdName=Tommy1961, createdTime=Tue Dec 19 19:50:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687007, encodeId=90af168e00780, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Jul 19 13:50:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272766, encodeId=a56d2e2766d8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/19/65b621d4a385e517982f632daf4124bb.jpg, createdBy=93302217036, createdName=李香香, createdTime=Tue Dec 26 21:52:18 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269988, encodeId=59ec126998860, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Dec 21 03:50:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270907, encodeId=6a972e090781, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Dec 20 12:26:49 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270650, encodeId=755f2e065008, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Dec 19 15:15:51 CST 2017, time=2017-12-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1751393, encodeId=5d561e51393d5, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03036305261, createdName=Tommy1961, createdTime=Tue Dec 19 19:50:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687007, encodeId=90af168e00780, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Jul 19 13:50:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272766, encodeId=a56d2e2766d8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/19/65b621d4a385e517982f632daf4124bb.jpg, createdBy=93302217036, createdName=李香香, createdTime=Tue Dec 26 21:52:18 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269988, encodeId=59ec126998860, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Dec 21 03:50:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270907, encodeId=6a972e090781, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Dec 20 12:26:49 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270650, encodeId=755f2e065008, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Dec 19 15:15:51 CST 2017, time=2017-12-19, status=1, ipAttribution=)]
    2017-12-26 李香香

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1751393, encodeId=5d561e51393d5, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03036305261, createdName=Tommy1961, createdTime=Tue Dec 19 19:50:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687007, encodeId=90af168e00780, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Jul 19 13:50:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272766, encodeId=a56d2e2766d8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/19/65b621d4a385e517982f632daf4124bb.jpg, createdBy=93302217036, createdName=李香香, createdTime=Tue Dec 26 21:52:18 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269988, encodeId=59ec126998860, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Dec 21 03:50:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270907, encodeId=6a972e090781, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Dec 20 12:26:49 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270650, encodeId=755f2e065008, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Dec 19 15:15:51 CST 2017, time=2017-12-19, status=1, ipAttribution=)]
    2017-12-21 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1751393, encodeId=5d561e51393d5, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03036305261, createdName=Tommy1961, createdTime=Tue Dec 19 19:50:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687007, encodeId=90af168e00780, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Jul 19 13:50:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272766, encodeId=a56d2e2766d8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/19/65b621d4a385e517982f632daf4124bb.jpg, createdBy=93302217036, createdName=李香香, createdTime=Tue Dec 26 21:52:18 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269988, encodeId=59ec126998860, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Dec 21 03:50:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270907, encodeId=6a972e090781, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Dec 20 12:26:49 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270650, encodeId=755f2e065008, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Dec 19 15:15:51 CST 2017, time=2017-12-19, status=1, ipAttribution=)]
    2017-12-20 天涯183

    非常好的文章.学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1751393, encodeId=5d561e51393d5, content=<a href='/topic/show?id=138290e787c' target=_blank style='color:#2F92EE;'>#视网膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90778, encryptionId=138290e787c, topicName=视网膜炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d03036305261, createdName=Tommy1961, createdTime=Tue Dec 19 19:50:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687007, encodeId=90af168e00780, content=<a href='/topic/show?id=5f688449023' target=_blank style='color:#2F92EE;'>#脉络膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84490, encryptionId=5f688449023, topicName=脉络膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a15828309522, createdName=12498568m59暂无昵称, createdTime=Thu Jul 19 13:50:00 CST 2018, time=2018-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272766, encodeId=a56d2e2766d8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/19/65b621d4a385e517982f632daf4124bb.jpg, createdBy=93302217036, createdName=李香香, createdTime=Tue Dec 26 21:52:18 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269988, encodeId=59ec126998860, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Dec 21 03:50:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270907, encodeId=6a972e090781, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Wed Dec 20 12:26:49 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270650, encodeId=755f2e065008, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Tue Dec 19 15:15:51 CST 2017, time=2017-12-19, status=1, ipAttribution=)]
    2017-12-19 天涯183

    非常好的文章.学习了

    0

相关资讯

急性心梗并发多器官功能不全 如何拯救患者于危难?

53岁男性患者,因发作性胸痛入院,此前于当地就医过程中突发意识丧失。入院后置入冠状动脉支架并药物治疗,患者仍觉胸闷。经检查,发现患者除急性心梗外还伴有急性肝功能损害、急性肾功能不全、血小板减少症等。尽管对症治疗,但入院后20小时内病情急剧恶化,多脏器严重衰竭。患者能否转危为安?对于多器官功能不全综合征应采取哪些治疗措施?详见以下病例?——

一文读懂:急性痛风发作时该怎么处理?

我这里说的痛风,指的是急性痛风性关节炎。在高尿酸的基础上,并在一定条件下,尿酸在关节形成结晶,刺激关节滑膜引起非细菌性炎症。一、什么情况下容易痛风发作?绝大多数痛风发生在第一跖趾关节,也就是大脚趾的关节。严重者逐渐向上蔓延,足背、足跟、踝、膝、指、腕和肘等关节。关节着凉(冬天没保暖或夏天吹空调)、饮酒是诱发因素。典型的发作过程是,大量饮酒后,上床睡觉时还没问题,后半夜因脚痛痛醒,而且越来越重,

Stroke:急性缺血性卒中患者:住院前使用SSRIs治疗对临床不良结局的影响如何?

选择性5-羟色胺再摄取抑制剂(SSRIs)是20世纪80年代陆续开发并试用于临床的一类新型抗抑郁药物。2017年11月,发表在《Stroke》上的一项多中心回顾性分析,对急性缺血性卒中患者住院前使用SSRIs治疗与溶栓后症状性颅内出血(sICH)和功能结局的相关性进行了评估。

急性心梗的罪魁祸首竟是……

男性患者,53岁,因反复心前区闷痛3日、神志不清10分钟入院,自诉有呼吸暂停,经检查诊断为中度阻塞型睡眠呼吸暂停综合征(OSAS)伴急性下壁心肌梗死。作为冠心病的危险因素,OSAS如何影响心血管健康?又有哪些方法治疗OSAS?

急性肺栓塞溶栓治疗致猝死 提醒临床医生……

急性肺栓塞是一种高发病率和高死亡率的心血管急症,早期诊断和治疗可以明显降低病死率。溶栓治疗是急性肺栓塞重要的治疗措施。溶栓治疗的主要并发症是出血,但溶栓治疗过程中发生猝死少有报道,本文结合2例急性肺栓塞溶栓治疗过程中发生的猝死临床资料,探讨急性肺栓塞溶栓过程中发生猝死的原因,旨在加强对急性肺栓塞溶栓疗法所致严重不良事件的认识。

急性胸痛:抢救过程分秒必争

患者以用力后突发胸痛、心悸为突出表现,急诊处理应以急性胸痛的诊治流程进行。具体步骤是什么?关于宽QRS波心动过速的诊断,有哪些鉴别方法?